Answers are grounded in this paper and cite their sources.
BACKGROUND: Modified-release (MR) trazodone formulations (prolonged-release [PR] and once-a-day [OAD]) are used to treat acute major depressive disorder (MDD), but there has been no quantitative synthesis of the available double-blind randomized evidence. We assessed the efficacy and tolerability of MR trazodone in adults with acute MDD. METHODS: We searched PubMed/MEDLINE, Europe PMC, and ClinicalTrials.gov up to 24 February 2026 and Scopus up to 6 March 2026. We also screened the reference lists of the identified publications for randomized controlled trials (RCTs) of trazodone PR or OAD in adults with acute MDD. Random-effects meta-analyses were performed when at least 2 trials were available. FINDINGS: Five primary RCTs (N=1329 randomized) met the inclusion criteria: 2 were placebo-controlled and 3 were active-controlled. Compared with placebo, MR trazodone improved HAM-D-17 scores (mean difference in symptom improvement: 2.49; 95% CI: 1.48-3.51) and increased the response rate (risk ratio [RR]: 1.44; 95% CI: 1.19-1.75). Remission rates were higher but imprecise (RR: 1.32; 95% CI: 0.93-1.88). Discontinuation due to adverse events occurred more frequently than with placebo (RR: 3.57; 95% CI: 1.79-7.10). In head-to-head trials, the estimates versus SSRIs were imprecise and did not demonstrate equivalence. A single venlafaxine XR trial favored venlafaxine. CONCLUSIONS: On the basis of 2 placebo-controlled trials, MR trazodone was found to be more effective than a placebo for reducing acute adult MDD symptoms in the short term. Sparse active-comparator evidence does not demonstrate superiority or equivalence compared with standard antidepressants. Real-world data may provide complementary information when insomnia or anxious distress is prominent.
No takes yet. Share an insight, caveat, or question.
Martiadis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: